Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product -- Ignore unavailable to you. Want to Upgrade?

To: art slott who wrote (1049)	4/1/1999 12:09:00 AM
From: muddphudd	Read Replies (1) \| Respond to of 1837

Duramed Pharmaceuticals Partners with Cardinal Health and Cardinal MarketFORCE for Distribution and Sales of Cenestin * Cardinal Health Subsidiary Focuses on Product Launch Services * Cardinal MarketFORCE Senior Management Brings In-Depth Experience Marketing to Specialists and Primary Care Physicians in Women's Health CINCINNATI, March 30 /PRNewswire/ -- Duramed Pharmaceuticals, Inc. (Nasdaq: DRMD - news) today announced that it has finalized an agreement to partner with Cardinal MarketFORCE, a Cardinal Health, Inc. (NYSE: CAH - news) offering that provides contract sales and marketing services, for launch-related and ongoing sales, marketing and distribution support for Cenestin(TM) (synthetic conjugated estrogens, A). Cenestin, the new plant-derived synthetic conjugated estrogens product for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, was approved for marketing by the U.S. Food and Drug Administration on March 24, 1999. Under the terms of the three-year agreement, Cardinal will recruit, train and deploy a team of dedicated, full-time sales professionals and experienced sales managers. The team will have the critical mass necessary to reach the targeted women's health market. In addition, Cardinal's Distribution Company will work with Duramed to maximize initial Cenestin stocking and product awareness. In return, Duramed will compensate Cardinal according to a fixed schedule with performance incentives for achievement of certain market share targets. At the end of the three-year period, the sales team will transition to full-time Duramed employees.